Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal

William C.S. Cho, PhD, RCMP, FHKIMLS, FHKSMDS, Chartered Scientist (UK), FIBMS (UK). Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Dr. Cho’s primary research interests focus on cancer research to discover biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, bioinformatics, and next-generation sequencing technologies. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, noncoding RNA, traditional Chinese medicine, and dozens of books (including An Omics Perspective on Cancer Research, MicroRNAs in Cancer Translational Research, Drug Repurposing in Cancer Therapy: Approaches and Applications, Supportive Cancer Care with Chinese Medicine, etc.). The cumulative impact factor of journals exceeds 4500, and the papers have been cited >25,000 times. Dr. Cho is listed among the top 2% of the most influential scientists in the world. In addition, Dr. Cho has served as a research grant reviewer for many international research funds, including the Hope Funds for Cancer Research (United States), Cancer Research (United Kingdom), National Medical Research Council (Singapore), etc.

1. Therapeutic antibodies against cancer – A step toward the treatment
2. Anti-CD20 antibody treatment for B-cell malignancies
3. Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways
4. Non-Hodgkin’s lymphoma treated with anti-CD20 antibody-based immunochemotherapy
5. Targeted therapies for follicular lymphoma
6. Treatment of relapsed follicular lymphoma
7. New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
8. Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma
9. Therapeutic options for rituximab-resistant patients
10. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies
11. Kinetic exclusion assay using cellular membranes for affinity determination of anti-CD20 antibody
12. Clinical efficacy of anti-CD20 antibodies in autoimmune diseases
13. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis
14. Anti-CD20 antibodies in glomerular disease, their resistance and reversal approaches
15. Adverse events following rituximab therapy in pemphigus patients
16. Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
17. Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases
18. Highlights and perspectives by the contributors of the volume (resistance to anti-CD20 antibodies and approaches for their reversals)